Ernexa Therapeutics Inc.
ERNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $125,235 | $143,478 | $147,363 | $2,708,415 |
| - Cash | $1,729 | $7,575 | $11,446 | $16,985 |
| + Debt | $684 | $41,843 | $4,138 | $2,723 |
| Enterprise Value | $124,190 | $177,746 | $140,055 | $2,694,153 |
| Revenue | $582 | $68 | $0 | $0 |
| % Growth | 755.9% | – | – | – |
| Gross Profit | $486 | -$168 | $0 | $0 |
| % Margin | 83.5% | -247.1% | – | – |
| EBITDA | -$36,119 | -$19,934 | -$24,007 | -$121,948 |
| % Margin | -6,206% | -29,314.7% | – | – |
| Net Income | -$44,539 | -$21,668 | -$24,579 | -$122,545 |
| % Margin | -7,652.7% | -31,864.7% | – | – |
| EPS Diluted | -1.57 | -4.08 | -8.06 | -56.61 |
| % Growth | 61.5% | 49.4% | 85.8% | – |
| Operating Cash Flow | -$15,836 | -$20,408 | -$20,976 | -$23,488 |
| Capital Expenditures | -$369 | -$19 | -$297 | -$154 |
| Free Cash Flow | -$16,205 | -$20,427 | -$21,273 | -$23,642 |